GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Catalyst Pharmaceuticals Inc (FRA:CN2) » Definitions » E10

Catalyst Pharmaceuticals (FRA:CN2) E10 : €0.29 (As of Dec. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Catalyst Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Catalyst Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2024 was €0.420. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €0.29 for the trailing ten years ended in Dec. 2024.

During the past 12 months, Catalyst Pharmaceuticals's average E10 Growth Rate was 114.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Catalyst Pharmaceuticals was 45.00% per year. The lowest was 4.20% per year. And the median was 11.35% per year.

As of today (2025-03-20), Catalyst Pharmaceuticals's current stock price is €19.76. Catalyst Pharmaceuticals's E10 for the quarter that ended in Dec. 2024 was €0.29. Catalyst Pharmaceuticals's Shiller PE Ratio of today is 68.14.

During the past 13 years, the highest Shiller PE Ratio of Catalyst Pharmaceuticals was 950.50. The lowest was 70.07. And the median was 114.33.


Catalyst Pharmaceuticals E10 Historical Data

The historical data trend for Catalyst Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Catalyst Pharmaceuticals E10 Chart

Catalyst Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.10 -0.05 0.04 0.13 0.29

Catalyst Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.13 0.16 0.19 0.22 0.29

Competitive Comparison of Catalyst Pharmaceuticals's E10

For the Biotechnology subindustry, Catalyst Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Catalyst Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Catalyst Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Catalyst Pharmaceuticals's Shiller PE Ratio falls into.



Catalyst Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Catalyst Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=0.42/133.1571*133.1571
=0.420

Current CPI (Dec. 2024) = 133.1571.

Catalyst Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201503 -0.065 99.621 -0.087
201506 -0.053 100.684 -0.070
201509 -0.045 100.392 -0.060
201512 -0.064 99.792 -0.085
201603 -0.063 100.470 -0.083
201606 -0.053 101.688 -0.069
201609 -0.045 101.861 -0.059
201612 -0.047 101.863 -0.061
201703 -0.056 102.862 -0.072
201706 -0.045 103.349 -0.058
201709 -0.042 104.136 -0.054
201712 -0.051 104.011 -0.065
201803 -0.049 105.290 -0.062
201806 -0.051 106.317 -0.064
201809 -0.069 106.507 -0.086
201812 -0.123 105.998 -0.155
201903 -0.009 107.251 -0.011
201906 0.089 108.070 0.110
201909 0.118 108.329 0.145
201912 0.063 108.420 0.077
202003 0.090 108.902 0.110
202006 0.080 108.767 0.098
202009 0.348 109.815 0.422
202012 0.090 109.897 0.109
202103 0.059 111.754 0.070
202106 0.091 114.631 0.106
202109 0.085 115.734 0.098
202112 0.080 117.630 0.091
202203 0.109 121.301 0.120
202206 0.189 125.017 0.201
202209 0.202 125.227 0.215
202212 0.208 125.222 0.221
202303 0.243 127.348 0.254
202306 0.305 128.729 0.315
202309 -0.272 129.860 -0.279
202312 0.284 129.419 0.292
202403 0.175 131.776 0.177
202406 0.307 132.554 0.308
202409 0.315 133.029 0.315
202412 0.420 133.157 0.420

Add all the adjusted EPS together and divide 10 will get our e10.


Catalyst Pharmaceuticals  (FRA:CN2) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Catalyst Pharmaceuticals's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=19.76/0.29
=68.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Catalyst Pharmaceuticals was 950.50. The lowest was 70.07. And the median was 114.33.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Catalyst Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of Catalyst Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Catalyst Pharmaceuticals Business Description

Traded in Other Exchanges
Address
355 Alhambra Circle, Suite 801, Coral Gables, FL, USA, 33134
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).

Catalyst Pharmaceuticals Headlines

No Headlines